Mycenax Biotech Inc., leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Vectron Biosolutions AS, a Norway-based service provider focused on developing broad-host-range vector technology for industrial production of recombinant proteins, today announced they have signed a cooperation agreement.
Under the terms of the agreement, Vectron and Mycenax will join forces to offer the industry a superior and complete solution for industrial microbial production of therapeutic proteins. Vectron will use its proprietary VB Expression technology platform, to develop robust and cost-efficient microbial strains for production of therapeutic proteins. The microbial strains will be transferred to Mycenax’ state-of-the-art biopharmaceutical manufacturing facility for the production of pre-clinical and clinical materials. The combined services of Mycenax and Vectron fulfill the needs of CDMO customers who require protein production with large scale, low cost, and high quality.
In the past, Mycenax has successfully established various innovative biopharmaceutical manufacturing technologies, both through its own R&D capability and collaboration with international organizations. The goal is to support customers in developing and manufacturing highly competitive biopharmaceutical products.
Pei-Jiun Chen, President of Mycenax, said: “Microbial strains have the advantages of low cost, easy scale-up, and short production cycle. Therefore, many biotech companies choose microbial systems to produce their products. By collaborating with Vectron, Mycenax can offer a better total solution for customers choosing microbial systems”
The product yield plays a critical role for the production of recombinant proteins. The average protein production of a microbial cell line on the market is about 1-2 g/L. In contrast, Vectron's proprietary technology platform can achieve stable microbial strains with yields of up to 50 g/L. This increase in productivity significantly improves the COG and hence the competitiveness of the product.
Vectron is based on the knowledge gained over decades of academic research and development by Professor Svein Valla and Dr. Trond Erik Aune at the Department of Biotechnology at the University of Science and Technology in Trondheim, Norway. Professor Valla was a world-leading expert on gene expression in bacteria and plasmid design and he developed a novel expression vector system by combining features of the RK2 plasmid with the promoter system from the pWW0 plasmid. Vectron is able to design and identify the most appropriate microbial expression vector for maximized protein yield.
Dr. Trond Erik Aune, Chief Executive Officer of Vectron, said: “Through the cooperation with Mycenax, we can extend the services to our customers from strain development to complete CMC development and CDMO services. This is a win-win situation for Vectron, Mycenax, and our customers.”
The combined services of Mycenax and Vectron target international biopharmaceutical companies developing novel biological drugs as well as biosimilar developers that want to reduce their production costs.
About Vectron Biosolutions AS
Vectron Biosolutions AS supplies the life science industries with superior technologies and solutions for robust and cost-efficient production of recombinant proteins in E. coli and other bacteria.
For more information, please visit www.vectronbiosolutions.com.
Mycenax Biotech Inc., leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Vectron Biosolutions AS, a Norway-based service provider focused on developing broad-host-range vector technology for industrial production of recombinant proteins, today announced they have signed a cooperation agreement.
Under the terms of the agreement, Vectron and Mycenax will join forces to offer the industry a superior and complete solution for industrial microbial production of therapeutic proteins. Vectron will use its proprietary VB Expression technology platform, to develop robust and cost-efficient microbial strains for production of therapeutic proteins. The microbial strains will be transferred to Mycenax’ state-of-the-art biopharmaceutical manufacturing facility for the production of pre-clinical and clinical materials. The combined services of Mycenax and Vectron fulfill the needs of CDMO customers who require protein production with large scale, low cost, and high quality.
In the past, Mycenax has successfully established various innovative biopharmaceutical manufacturing technologies, both through its own R&D capability and collaboration with international organizations. The goal is to support customers in developing and manufacturing highly competitive biopharmaceutical products.
Pei-Jiun Chen, President of Mycenax, said: “Microbial strains have the advantages of low cost, easy scale-up, and short production cycle. Therefore, many biotech companies choose microbial systems to produce their products. By collaborating with Vectron, Mycenax can offer a better total solution for customers choosing microbial systems”
The product yield plays a critical role for the production of recombinant proteins. The average protein production of a microbial cell line on the market is about 1-2 g/L. In contrast, Vectron's proprietary technology platform can achieve stable microbial strains with yields of up to 50 g/L. This increase in productivity significantly improves the COG and hence the competitiveness of the product.
Vectron is based on the knowledge gained over decades of academic research and development by Professor Svein Valla and Dr. Trond Erik Aune at the Department of Biotechnology at the University of Science and Technology in Trondheim, Norway. Professor Valla was a world-leading expert on gene expression in bacteria and plasmid design and he developed a novel expression vector system by combining features of the RK2 plasmid with the promoter system from the pWW0 plasmid. Vectron is able to design and identify the most appropriate microbial expression vector for maximized protein yield.
Dr. Trond Erik Aune, Chief Executive Officer of Vectron, said: “Through the cooperation with Mycenax, we can extend the services to our customers from strain development to complete CMC development and CDMO services. This is a win-win situation for Vectron, Mycenax, and our customers.”
The combined services of Mycenax and Vectron target international biopharmaceutical companies developing novel biological drugs as well as biosimilar developers that want to reduce their production costs.
About Vectron Biosolutions AS
Vectron Biosolutions AS supplies the life science industries with superior technologies and solutions for robust and cost-efficient production of recombinant proteins in E. coli and other bacteria.
For more information, please visit www.vectronbiosolutions.com.